Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

 Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

Shots:

  • The companies collaborated to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal space
  • The focus of the agreement is to merge Pear’s expertise in PDTs with Ironwood’s GI franchise and clinical expertise and to expand Pear’s portfolio outside the central nervous system
  • The collaboration will provide an opportunity to develop first-in-class therapies, helping patients with GI disease to reach better outcomes

Click here to­ read full press release/ article | Ref: Pear Therapeutics  | Image: PMLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post